Literature DB >> 11551662

The cost of hepatitis C and the cost-effectiveness of its prevention.

A Shiell1, M G Law.   

Abstract

Hepatitis C infection is an emerging problem in public health and is now the most common blood-borne infection. The virus imposes a significant personal and social burden on those infected, as well as substantial costs to the health care system. In this paper we report an estimate of the costs of hepatitis C and consider the role such information might play in determining an appropriate preventive strategy. Preventing a single case of HCV would release resources valued Aus $6000 and Aus $19,000, depending on whether production loses were included. This information can be used to derive cost-effectiveness thresholds for any preventive activity, but is not in itself necessary in determining health priorities. Information on the marginal cost-effectiveness of preventive methods is both necessary and sufficient.

Entities:  

Mesh:

Year:  2001        PMID: 11551662     DOI: 10.1016/s0168-8510(01)00159-2

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  4 in total

1.  Prevalence of Hepatitis B, C, HIV and syphilis markers among refugees in Bari, Italy.

Authors:  Silvio Tafuri; Rosa Prato; Domenico Martinelli; Livio Melpignano; Maria De Palma; Michele Quarto; Cinzia Germinario
Journal:  BMC Infect Dis       Date:  2010-07-20       Impact factor: 3.090

2.  N-acetyl cysteine therapy in acute viral hepatitis.

Authors:  Huseyin Gunduz; Oguz Karabay; Ali Tamer; Resat Ozaras; Ali Mert; Omer Fehmi Tabak
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

3.  Labour force participation among individuals with hepatitis C in the US.

Authors:  Philip Jacobs; Ying Chu Ng; Tania Stafinski; Roger Dodd; Bryce Larke; Winnie Wong
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Labour productivity losses caused by premature death associated with hepatitis C in Spain.

Authors:  Juan Oliva-Moreno; Luz M Peña-Longobardo; Sonia Alonso; Antonio Fernández-Bolaños; María Luisa Gutiérrez; Álvaro Hidalgo-Vega; Elsa de la Fuente; Conrado M Fernández-Rodríguez
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-06       Impact factor: 2.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.